Abstract:BackgroundMiddle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that emerged in 2012, causes severe and fatal acute respiratory illness in man. Its high mortality (roughly 38%) has raised public fear worldwide, calling for the development of effective and safe therapeutics to combat MERS-CoV infection. On the basis of our previous work in development of peptide fusion inhibitors against HIV and SARS-CoV, and the crystal structure of the six-helix-bundle core of the MERS-CoV spike protein, we identified a peptide derived from the MERS-CoV S protein S2 subunit HR2 domain (HR2P) with a potent inhibitory activity against S-protein-mediated cell–cell fusion. Here, we tested an HR2P analogue with improved pharmaceutical properties, HR2P-M2, for its inhibitory activity against MERS-CoV infection in vitro and in vivo (appendix).MethodsWe assessed the anti-MERS-CoV activities of HR2P-M2 in vitro with pseudotyped MERS-CoVs in cell culture and in vivo with live MERS-CoVs in hDPP4-transgenic mice. The activities of HR2P-M2 to form six-helix bundles with HR1 peptides and to block fusion core formation between HR1 and HR2 peptides were studied using methods such as circular dichroism, N-PAGE, and FN-PAGE.FindingsHR2P-M2 was highly effective in blockade of cell–cell fusion mediated by MERS-CoV S proteins and inhibition of infection by MERS pseudoviruses expressing MERS-CoV S protein with or without mutation in the HR1 region, with IC50 (the concentration causing 50% inhibition) less than 0·7 μM. HR2P-M2 bound to the HR1 peptide to form stable six-helix bundles and blocked fusion core formation between the HR1 and HR2 peptides. Intranasal administration of HR2P-M2 before viral challenge fully protected hDPP4-transgenic mice (n=5) from MERS-CoV infection, whereas all the untreated mice (n=5) died 8 days after viral challenge.InterpretationOur findings suggest that the HR2P-M2 peptide merits further development as an effective and safe anti-MERS-CoV drug, alone or in combination with other antiviral drugs, to treat MERS-CoV-infected patients and to prevent the disease in high-risk populations, including health-care workers and family members of patients.FundingThis work was supported by grants from the National Science Fund of China (81173098 and 81361120378 to SJ, 81373456 to LL), the National 973 Program of China (2012CB519001 to SJ), and the US National Biocontainment Laboratories Operations Support (5UC7AI094660-05 to C-TKT). The funders had no role in interpretation of the findings and writing of this abstract.

[Development of Peptidic MERS-CoV Entry Inhibitors].

Middle East Respiratory Syndrome Coronavirus (Mers-Cov) Entry Inhibitors Targeting Spike Protein

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies

Development of Small-Molecule MERS-CoV Inhibitors.

MERS-CoV spike protein: a key target for antivirals

Structure-based Discovery of Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor

Intranasally Administered Peptidic Viral Fusion Inhibitor Protected Hdpp4 Transgenic Mice from MERS-CoV Infection

Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors.

[Small Molecular Agents Against MERS-CoV Infection].

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain

Bioinformatics Analysis on Potential Anti-Viral Targets Against Spike Protein of MERS-CoV

Complex Structure of Mers-Cov Spike Glycoprotein with Human Receptor Dpp4

Protective Effect Of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against Mers-Cov Infection

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Designed miniproteins potently inhibit and protect against MERS-CoV

Sulfated Glycans Inhibit the Interaction of MERS-CoV Receptor Binding Domain with Heparin

An in silico approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Current Advancements and Potential Strategies in the Development of MERS-CoV Vaccines

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV.

Potent Mers-Cov Fusion Inhibitory Peptides Identified From Hr2 Domain In Spike Protein Of Bat Coronavirus Hku4